Menu Search
Equities

Kane Biotech Inc

KNE:CVE

Kane Biotech Inc

Actions
  • Price (CAD)0.14
  • Today's Change0.005 / 3.70%
  • Shares traded36.00k
  • 1 Year change+86.67%
  • Beta0.5406
Data delayed at least 15 minutes, as of Sep 20 2024 20:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in CADIncome statement in CADView more

Year on year Kane Biotech Inc's revenues fell -94.42% from 2.67m to 148.98k. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from a loss of 3.89m to a larger loss of 5.03m.
Gross margin60.54%
Net profit margin-723.31%
Operating margin-597.09%
Return on assets-113.43%
Return on equity--
Return on investment--
More ▼

Cash flow in CADView more

In 2023, Kane Biotech Inc increased its cash reserves by 70.94%, or 783.83k. Cash Flow from Financing totalled 2.98m or 2,001.68% of revenues. In addition the company used 2.08m for operations while cash used for investing totalled 116.14k.
Cash flow per share-0.0406
Price/Cash flow per share--
Book value per share-0.0055
Tangible book value per share-0.011
More ▼

Balance sheet in CADView more

Kane Biotech Inc appears to have a weak balance sheet, highlighted by its negative owner's equity. Additionally, this company's debt load is greater than its assets while day-to-day operations are losing money.
Current ratio0.8237
Quick ratio0.5679
Total debt/total equity--
Total debt/total capital1.43
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.